Logo

Olema Pharmaceuticals, Inc.

OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive… read more

Healthcare

Biotechnology

2 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$10.74

Price

+9.70%

$0.95

Market Cap

$737.126m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$364k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$142.295m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$2.04

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$345.236m

$382.002m

Assets

$36.766m

Liabilities

$1.755m

Debt
Debt to Assets

0.5%

-

Debt to EBITDA
Free Cash Flow

-$127.003m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases